-
Most Recent
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Anemia Drug Recalled After Patient Deaths
Omontys, a drug meant to treat anemia in dialysis patients, from Affymax has been recalled after a number of patients died shortly after receiving it.
Get This Blazing Hot Biotech for a Reasonable Price
A consolidation in Celgene Corp. is giving traders the perfect opportunity to buy at a bargain.
Gilead Sciences Headed for New Highs
Gilead Sciences is in an orderly bull market characterized by breakouts and breakaway gaps.
Top 10 Dow Dividend Stocks for February
Income investors could do a lot worse than buying into these venerable blue chips -- especially the stock that continues to hold the crown.
3 Healthcare Stocks Ready for a Breather
It's the hottest sector in the S&P 500 so far this year, and that means some big-name pullbacks are likely. Here are three likely candidates.
Biotech Movers: Keryx Jumps, Sarepta Slips
Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades.
It’s an ETF Picker’s Market
In some sectors, it just doesn’t pay to go stock shopping when you can buy the ETF instead. But that's some -- not all. Here are a few examples.
Keryx: An Important Biotech Reality Check in 5, 4, 3 …
This stock's tripling in the past month is your prototypical biotech "win." But if you don't lock in your gains now, you don't understand the game.
Biotech Movers: Arena Gets Warned, MAP Gets an Offer
Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals.
Flu’s Pain Is All Gain for These Companies
As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers.
OPKO Health’s Healthy Buyout Binge
This healthcare name is rapidly building up a business worth watching. And the possibility of OPKO itself getting bought out isn't too remote.
Surprise! Dendreon Doesn’t Stink Anymore
It took three years, but this biotech may be quietly finding its footing as its innovative Provenge prostate-cancer fighter gains credibility.
Why Pfizer Has to Buy Agila Injectable Drugs
A quick infusion of generic drugs -- via India's Agila Specialties -- could lessen the blow from Pfizer's expiring patents.
Biotech Movers: Dendreon Pops, ArQule Drops
An analyst upgrade on DNDN lifted the shares 21% last Friday, but mid-stage trial failure of a colorectal drug sank ARQL 11% the same day.
Now That the Vivus Dust Has Settled …
The diet-drug maker deserves a second -- more optimistic -- look after the hype and unmeetable expectations have passed.
4 Reasons Celgene Is the Real Deal
Celgene has reached all-time highs in the wake of the firm’s boffo reviews at this week’s JPMorgan Healthcare Conference ... and it's still worth buying.
Alcoa: From Bellwether to Red Herring
Alcoa's fourth-quarter earnings expectations look rosy -- which is better than you can say for the broader market
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
